Tolvaptan drug tested in healthy men for safety and body processing
NCT ID NCT07166887
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial tested the drug tolvaptan (7.5mg) in 12 healthy men to see how the body absorbs, processes, and eliminates it. Participants took the tablet eight times over nine days. The study measured drug levels in the blood and checked for side effects, but it was not designed to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tolvaptan
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.